Regulatory Lilly bags FDA okay for Wegovy pill rival orforglipron PharmaphorumEli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo RivalryNext: FDA approves Lilly obesity pill, triggering battle with Novo Nordisk Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
